A Novel Nomogram for Identifying the Patients at Risk for Rapid Progression of Advanced Hormone-Sensitive Prostate Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Yao S, Zhang H, Chen Z, et al. Promotion of graphitic carbon oxidation via stimulating CO2 desorption by calcium carbonate. J Hazard Mater. 2019;363:10–15. doi:10.1016/j.jhazmat.2018.09.048
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–1192. doi:10.1111/j.1742-1241.2011.02799.x
   PubMed Web of Science ®Google Scholar
• Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (intergroup study 0162) and 9916. J Clin Oncol. 2009;27(15):2450–2456. doi:10.1200/JCO.2008.19.9810
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. doi:10.1056/NEJMoa1503747
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177. doi:10.1016/S0140-6736(15)01037-5
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Cimadamore A, et al. Is there a role for immunotherapy in prostate cancer? Cells. 2020;9(9):2051. doi:10.3390/cells9092051
   PubMed Web of Science ®Google Scholar
• Mollica V, Rizzo A, Rosellini M, et al. Bone targeting agents in patients with metastatic prostate cancer: state of the art. Cancers. 2021;13(3):546. doi:10.3390/cancers13030546
   PubMed Web of Science ®Google Scholar
• Rosellini M, Santoni M, Mollica V, et al. Treating prostate cancer by antibody-drug conjugates. Int J Mol Sci. 2021;22(4):1551. doi:10.3390/ijms22041551
   PubMed Web of Science ®Google Scholar
• Rizzo A, Santoni M, Mollica V, Fiorentino M, Brandi G, Massari F. Microbiota and prostate cancer. Semin Cancer Biol. 2022;86(Pt 3):1058–1065. doi:10.1016/j.semcancer.2021.09.007
   PubMedGoogle Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–1314. doi:10.1016/j.eururo.2006.09.019
   PubMed Web of Science ®Google Scholar
• Magistro G, Keller P, Westhofen T, et al. The significance of a high preoperative PSA level for the detection of incidental prostate cancer in LUTS patients with large prostates. World J Urol. 2021;39(5):1481–1487. doi:10.1007/s00345-020-03321-w
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu H, Liu S, et al. Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients. Int Urol Nephrol. 2017;49(7):1111–1117. doi:10.1007/s11255-017-1591-1
   PubMed Web of Science ®Google Scholar
• Panaiyadiyan S, Kumar R. Prostate cancer nomograms and their application in Asian men: a review. Prostate Int. 2023;2287–8882. doi:10.1016/j.prnil.2023.07.004
   Google Scholar
• Camp R, Dolled-Filhart M, Rimm D. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Ma CG, Ye D-W, Li C-L, et al. [Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]. Zhonghua Wai Ke Za Zhi. 2008;46(12):921–925. Chinese.
   PubMedGoogle Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36. 1080.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, Phase 3 trial. Lancet Oncol. 2019;20(5):686–700. doi:10.1016/S1470-2045(19)30082-8
   PubMed Web of Science ®Google Scholar
• Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Prevalence of lower urinary tract symptoms in men aged 45–79 years: a population-based study of 40,000 Swedish men. BJU Int. 2004;94(3):327–331. doi:10.1111/j.1464-410X.2004.04930.x
   PubMed Web of Science ®Google Scholar
• Xia BW, Zhao SC, Chen ZP, et al. Relationship between serum total testosterone and prostate volume in aging men. Sci Rep. 2021;11(1):14122. doi:10.1038/s41598-021-93728-1
   PubMed Web of Science ®Google Scholar
• Duarsa GW, Sari YA, Oka AA, et al. Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients. Asian J Urol. 2021;8(3):289–297. doi:10.1016/j.ajur.2020.06.001
   PubMed Web of Science ®Google Scholar
• Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol. 2015;193(2):403–413. doi:10.1016/j.juro.2014.07.123
   PubMedGoogle Scholar
• Miura N, Mori K, Mostafaei H, et al. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. Int J Clin Oncol. 2020;25(11):1881–1891. doi:10.1007/s10147-020-01747-1
   PubMed Web of Science ®Google Scholar
• Xu SS, Li S, Xu HX, et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. World J Gastroenterol. 2020;26(8):828–838. doi:10.3748/wjg.v26.i8.828
   PubMed Web of Science ®Google Scholar
• Shen XB, Zhang YX, Wang W, Pan YY. The hemoglobin, albumin, lymphocyte, and platelet (HALP) score in patients with small cell lung cancer before first-line treatment with etoposide and progression-free survival. Med Sci Monit. 2019;25:5630–5639. doi:10.12659/MSM.917968
   PubMed Web of Science ®Google Scholar
• Kaya C, Caliskan S, Sungur M, Aydın C. HALP score and albumin levels in men with prostate cancer and benign prostate hyperplasia. Int J Clin Pract. 2021;75(3):e13766. doi:10.1111/ijcp.13766
   PubMed Web of Science ®Google Scholar
• Guo Y, Shi D, Zhang J, et al. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score is a novel significant prognostic factor for patients with metastatic prostate cancer undergoing cytoreductive radical prostatectomy. J Cancer. 2019;10(1):81–91. doi:10.7150/jca.27210
   PubMed Web of Science ®Google Scholar
• Heetman JG, Soeterik TFW, Wever L, et al. A side-specific nomogram for extraprostatic extension may reduce the positive surgical margin rate in radical prostatectomy. World J Urol. 2022;40(12):2919–2924. doi:10.1007/s00345-022-04191-0
   PubMed Web of Science ®Google Scholar
• Lin Z, Li Y, Wu J, et al. Nomogram for prediction of prolonged postoperative ileus after colorectal resection. BMC Cancer. 2022;22(1):1273. doi:10.1186/s12885-022-10377-x
   PubMed Web of Science ®Google Scholar
• Nguyen HT, Xue H, Firlej V, et al. Reference-free transcriptome signatures for prostate cancer prognosis. BMC Cancer. 2021;21(1):394. doi:10.1186/s12885-021-08021-1
   PubMed Web of Science ®Google Scholar
• Zhang S, Xu Y, Hui X, et al. Improvement in prediction of prostate cancer prognosis with somatic mutational signatures. J Cancer. 2017;8(16):3261–3267. doi:10.7150/jca.21261
   PubMed Web of Science ®Google Scholar
• Zhou E, Zhang B, Zhu K, Schaafsma E, Kumar RD, Cheng C. A TMPRSS2-ERG gene signature predicts prognosis of patients with prostate adenocarcinoma. Clin Transl Med. 2020;10(8):e216. doi:10.1002/ctm2.216
   PubMed Web of Science ®Google Scholar